Rimmyrah®

ACTIVE PRINCIPLE:
Ranibizumab

INDICATION:
wet macular degeneration
Macular edema
diabetic complications
degenerative myopia
Choroidal neovascularization

DATE:
05/01/2024

STATUS:
Authorized